Skip to content
value.today

Grace Therapeutics, Inc.

Grace Therapeutics, Inc. is listed today as Grace Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Grace Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2026$10 MPrivate placement after listing$10 to $50 million

Grace Therapeutics, Inc.: Private sale, Aug 2026

Investors in this round

9 investors had bought by the notice of Aug 11, 2026: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
$1
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$560,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Amresh Loch Kumar · Executive Officer · VP of Program Management
  • Dr. R. Loch Macdonald · Executive Officer · Chief Medical Officer
  • Prashant Kohli · Executive Officer, Director · Chief Executive Officer
  • Robert J. DelAversano · Executive Officer · Vice President, Finance, Principal Financial Officer and Principal Accounting Officer
  • A. Brian Davis · Director
  • Edward George Neugeboren · Director
  • S. George Kottayil · Director
  • Vimal Kavuru · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Craig-Hallum Capital Group (CRD 000121395) · Minneapolis, MinnesotaSold in CT, DE, MA, NY, TX, and outside the US

Signed by Prashant Kohli, Ceo. Source: SEC Form D, newest notice filed Aug 11, 2026. Read the notice at the SEC.

equitySEC
Feb 2025$15 MPrivate placement after listing$10 to $50 million

Grace Therapeutics, Inc.: Private sale, Feb 2025

Investors in this round

14 investors had bought by the notice of Feb 25, 2025: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $30 M offered; $15 M still to sell
Smallest investment taken
$1
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$1,530,011
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Amresh Kumar · Executive Officer · VP of Program Management
  • Carrie D'Andrea · Executive Officer · VP Clinical Operations
  • Dr. R. Loch Macdonald · Executive Officer · Chief Medical Officer
  • Prashant Kohli · Director, Executive Officer · Chief Executive Officer
  • Robert J. DelAversano · Executive Officer · Vice President, Finance, Principal Financial Officer and Principal Accounting Officer
  • A. Brian Davis · Director
  • Edward Neugeboren · Director
  • S. George Kottayil · Director
  • Vimal Kavuru · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • TD Securities (USA) LLC (CRD 18476) · New York, New YorkSold in CT, DE, MD, NC, NY, OR, SD, TX

Remarks in the notice

  • On fees: “Placement agent received a cash fee of $764,999 upon closing and is entitled to receive cash fees of up to $765,012 in connection with exercises of warrants purchased in the private placement.”
  • On the amounts: “The offering amount reflects the aggregate purchase price received and exercise price due to the Company assuming cash exercise of all warrants issued to the accredited investors under Rule 506(b).”

Signed by Prashant Kohli, Ceo. Source: SEC Form D, newest notice filed Feb 25, 2025. Read the notice at the SEC.

equity, optionsSEC
Sep 2023$8 MPrivate placement after listing$2 to $10 million

Grace Therapeutics, Inc.: Private sale, Sep 2023

Investors in this round

4 investors had bought by the notice of Oct 10, 2023: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $15 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Quebec, Canada

People named in the notice

  • Amresh Kumar · Executive Officer · VP of Product Management
  • Brian Ford · Executive Officer · Interim Chief Financial Officer
  • Carrie D'Andrea · Executive Officer · Clinical Operations
  • Dr. R. Loch Macdonald · Executive Officer · Chief Medical Officer
  • Prashant Kohli · Executive Officer
  • Donald Olds · Director
  • Michael Derby · Director
  • Vimal Kavuru · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The offering amount reflects the aggregate purchase price received and exercise price due to the Company assuming cash exercise of all warrants issued to the accredited investors under Rule 506(b).”

Signed by Prashant Kohli, Ceo. Source: SEC Form D, newest notice filed Oct 10, 2023. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Grace Therapeutics, Inc. had no revenue when it filed its newest notice of a funding round (Aug 2026).

    SEC Form D (revenue range) · Aug 2026

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Aug 2026

Products and services#

No products or services of Grace Therapeutics, Inc. are on record.

Investors#

No investor of Grace Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Grace Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Grace Therapeutics, Inc.
NameRoleNamed in
Amresh Loch KumarVP of Program ManagementAug 2026
Dr. R. Loch MacdonaldChief Medical OfficerAug 2026
Prashant KohliChief Executive OfficerAug 2026
Robert J. DelAversanoVice President, Finance, Principal Financial Officer and Principal Accounting OfficerAug 2026
Amresh KumarVP of Program ManagementFeb 2025
Carrie D'AndreaVP Clinical OperationsFeb 2025
Brian FordInterim Chief Financial OfficerOct 2023
A. Brian DavisDirectorAug 2026
Edward George NeugeborenDirectorAug 2026
Prashant KohliChief Executive OfficerAug 2026
S. George KottayilDirectorAug 2026
Vimal KavuruDirectorAug 2026
Edward NeugeborenDirectorFeb 2025
Donald OldsDirectorOct 2023
Michael DerbyDirectorOct 2023

Went public since 2017. Its SEC number is that of a company listed on a stock exchange.